Patient P-01465
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Deteriorating
Nutritional resilience
Improving
Discontinuation risk
80%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −15% vs expected — Dietary Support Protocol NP-02
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 48 SC-12 recommended — Supportive Compound SC-12
- Day 49 Patient accepted — Started SC-12 in the companion
- Day 51 GI-04 recommended — GI Support Protocol GI-04
- Day 52 Patient accepted — Started GI-04 in the companion
- Day 55 No meaningful change — Supportive Compound SC-12
- Day 60 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- Inflammatory activity+10
- Toxicity+9
- GI instability+5
- Nutritional resilience+5
- Treatment adherence-5
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −15%
- Supportive Compound SC-12Day 48Result: no meaningful change
- GI Support Protocol GI-04Day 51Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
- WearableSleep 5.5 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 80 bpm
- WearableShort sleep window
- Inflammatory signalling ↑40
- BloodInflammatory load index 57
- WearableHRV 34 ms, trending down
- Drug metabolism and exposure ↑20
- BloodToxicity index 54
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 32 ms
- Sleep
- 5.8 h
- Steps
- 6,810
- Resting HR
- 78 bpm
Daily log: GI score 60, nutritional resilience 44, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.